These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 2492102)

  • 41. Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells.
    Siegall CB; Chaudhary VK; FitzGerald DJ; Pastan I
    Proc Natl Acad Sci U S A; 1988 Dec; 85(24):9738-42. PubMed ID: 3264406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells.
    Epstein SE; Siegall CB; Biro S; Fu YM; FitzGerald D; Pastan I
    Circulation; 1991 Aug; 84(2):778-87. PubMed ID: 1860221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
    Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin.
    Gawlak SL; Pastan I; Siegall CB
    Bioconjug Chem; 1993; 4(6):483-9. PubMed ID: 7508267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
    Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
    J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells.
    Kozak RW; Lorberboum-Galski H; Jones L; Puri RK; Willingham MC; Malek T; Fitzgerald DJ; Waldmann TA; Pastan I
    J Immunol; 1990 Oct; 145(8):2766-71. PubMed ID: 2212661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant toxins.
    Kreitman RJ; Pastan I
    Adv Pharmacol; 1994; 28():193-219. PubMed ID: 8080817
    [No Abstract]   [Full Text] [Related]  

  • 48. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
    Siegall CB
    Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
    Kreitman RJ; Bailon P; Chaudhary VK; FitzGerald DJ; Pastan I
    Blood; 1994 Jan; 83(2):426-34. PubMed ID: 8286741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40.
    Herbort CP; de Smet MD; Roberge FG; Nussenblatt RB; FitzGerald D; Lorberboum-Galski H; Pastan I
    Transplantation; 1991 Sep; 52(3):470-4. PubMed ID: 1897019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons.
    Ramachandran RV; Katzenstein DA; Wood R; Batts DH; Merigan TC
    J Infect Dis; 1994 Oct; 170(4):1009-13. PubMed ID: 7930696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of single-chain antibody (sFv)-toxin fusion proteins produced in vitro in rabbit reticulocyte lysate.
    Nicholls PJ; Johnson VG; Andrew SM; Hoogenboom HR; Raus JC; Youle RJ
    J Biol Chem; 1993 Mar; 268(7):5302-8. PubMed ID: 8444903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting growth factor receptors with fusion toxins.
    Kreitman RJ; FitzGerald D; Pastan I
    Int J Immunopharmacol; 1992 Apr; 14(3):465-72. PubMed ID: 1319965
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Targeted toxin therapy in the treatment of leukemia].
    Tojo A; Oshima Y
    Rinsho Ketsueki; 1995 Jun; 36(6):578-81. PubMed ID: 7543952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor binding is affected by structural determinants in the toxin domain of transforming growth factor-alpha-Pseudomonas exotoxin fusion proteins.
    Edwards GM; DeFeo-Jones D; Tai JY; Vuocolo GA; Patrick DR; Heimbrook DC; Oliff A
    Mol Cell Biol; 1989 Jul; 9(7):2860-7. PubMed ID: 2779550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro.
    Kameyama S; Kawamata H; Pastan I; Oyasu R
    J Cancer Res Clin Oncol; 1994; 120(9):507-12. PubMed ID: 8045915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein.
    Bush KA; Farmer KM; Walker JS; Kirkham BW
    Arthritis Rheum; 2002 Mar; 46(3):802-5. PubMed ID: 11920418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
    Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
    Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biological activity of a transforming growth factor-alpha--Pseudomonas exotoxin fusion protein in vitro and in vivo.
    Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
    J Ind Microbiol; 1991 Apr; 7(3):203-7. PubMed ID: 1367127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis.
    Bacha P; Forte SE; Perper SJ; Trentham DE; Nichols JC
    Eur J Immunol; 1992 Jul; 22(7):1673-9. PubMed ID: 1623918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.